Jean C. Tien
YOU?
Author Swipe
View article: Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer
Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer Open
Prostate cancer is driven by oncogenic transcription factor enhanceosomes comprising chromatin and epigenetic regulators. The lysine acetyltransferases p300 and CREB-binding protein (CBP) are key cofactors that activate enhancers through h…
View article: Cellular cartography reveals mouse prostate organization and determinants of castration resistance
Cellular cartography reveals mouse prostate organization and determinants of castration resistance Open
Inadequate response to androgen deprivation therapy (ADT) frequently arises in prostate cancer, driven by cellular mechanisms that remain poorly understood. Here, we integrated single-cell RNA sequencing, single-cell multiomics, and spatia…
View article: CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical models
CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical models Open
Inactivation of cyclin-dependent kinase 12 (CDK12) defines an immunogenic molecular subtype of prostate cancer characterized by genomic instability and increased intratumoral T cell infiltration. This study revealed that genetic or pharmac…
View article: Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity
Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity Open
FOXA1 is altered in 10 to 40% of prostate cancers, yet its oncogenic mechanisms remain uncharacterized in vivo. We developed knock-in mouse models representing distinct classes of FOXA1 mutations. Histopathological and multiomic analyses o…
View article: Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma Open
Ovarian cancer is the sixth leading cause of cancer death among American women, with most fatalities attributable to tubo-ovarian high-grade serous carcinoma (HGSC). This malignancy usually develops resistance to conventional chemotherapy,…
View article: Cellular cartography reveals mouse prostate organization and determinants of castration resistance
Cellular cartography reveals mouse prostate organization and determinants of castration resistance Open
Inadequate response to androgen deprivation therapy (ADT) frequently arises in prostate cancer, driven by cellular mechanisms that remain poorly understood. Here, we integrated single-cell RNA sequencing, single-cell multiomics, and spatia…
View article: CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13 Open
Biallelic loss of cyclin-dependent kinase 12 (CDK12) defines a metastatic castration-resistant prostate cancer (mCRPC) subtype. It remains unclear, however, whether CDK12 loss drives prostate cancer (PCa) development or uncovers pharmacolo…
View article: Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer Open
View article: Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies
Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies Open
View article: Corrigendum to “Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma” [Neoplasia, Volume 21, Issue 3 (2019) 322–330]
Corrigendum to “Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma” [Neoplasia, Volume 21, Issue 3 (2019) 322–330] Open
View article: Corrigendum to “Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma” [Neoplasia, Volume 21, Issue 3 (2019) 322–330]
Corrigendum to “Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma” [Neoplasia, Volume 21, Issue 3 (2019) 322–330] Open
View article: <i>CDK12</i>Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality
<i>CDK12</i>Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality Open
SUMMARY Biallelic loss of cyclin-dependent kinase 12 ( CDK12 ) defines a unique molecular subtype of metastatic castration-resistant prostate cancer (mCRPC). It remains unclear, however, whether CDK12 loss per se is sufficient to drive pro…
View article: PIKfyve controls dendritic cell function and tumor immunity
PIKfyve controls dendritic cell function and tumor immunity Open
The modern armamentarium for cancer treatment includes immunotherapy and targeted therapy, such as protein kinase inhibitors. However, the mechanisms that allow cancer-targeting drugs to effectively mobilize dendritic cells (DCs) and affec…
View article: Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies
Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies Open
SUMMARY The POU2F3-POU2AF2/3 (OCA-T1/2) transcription factor complex is the master regulator of the tuft cell lineage and tuft cell-like small cell lung cancer (SCLC). Here, we found that the POU2F3 molecular subtype of SCLC (SCLC-P) exhib…
View article: Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma
Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma Open
Neuroblastoma (NB) is a predominantly pediatric cancer with greater than 90% of cases arising in children under the age of five. More than half of patients have metastases detected at diagnosis, and high-risk disease is associated with fiv…
View article: Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA
Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA Open
View article: S Table 5 from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma
S Table 5 from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma Open
Supplementary Table 5
View article: Supplementary Figures from Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer
Supplementary Figures from Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer Open
This file includes Supplementary Figures S1-S8. Figure S1: Inhibition of EPZ6438 and ASO-EZH2 sensitizes enzalutamide-resistant LNCaP cells to enzalutamide or ASO-AR. Figure S2: Design and validation of sgRNA targeting EZH2. Figure S3: Gro…
View article: Supplementary Data from Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer
Supplementary Data from Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer Open
Supplementary information with additional materials and methods, references, and the legends for all supplementary figures.
View article: S Table 5 from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma
S Table 5 from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma Open
Supplementary Table 5
View article: cohort_primary from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma
cohort_primary from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma Open
bed file
View article: cohort_meta from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma
cohort_meta from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma Open
bed file
View article: Data from Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer
Data from Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer Open
Advanced prostate cancer initially responds to androgen deprivation therapy (ADT), but the disease inevitably recurs as castration-resistant prostate cancer (CRPC). Although CRPC initially responds to abiraterone and enzalutamide, the dise…
View article: S. Table 2 from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma
S. Table 2 from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma Open
IHC data of human samples (ZNF217)
View article: Table S2 from Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer
Table S2 from Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer Open
Supplementary Table 2 Cell-titer Glo raw data from epigenetic inhibitor screen.
View article: S Table 1 from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma
S Table 1 from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma Open
gCIS analysis of primary screen
View article: Supplementary Data from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma
Supplementary Data from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma Open
Supplementary figure
View article: S Table 3 from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma
S Table 3 from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma Open
gCIS analysis of metastases screen
View article: Supplementary Data from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma
Supplementary Data from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma Open
Supplementary figure
View article: S Table 4 from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma
S Table 4 from Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma Open
Supplementary Table 4